When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 107, Issue 9-10, 2013, Pages 575-584

  Siebert, Uwe ^a,b,c,d   Rochau, Ursula ^a,b   Claxton, Karl ^e  

^a UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^b Center for Personalized Cancer Medicine GmbH   (Austria)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

evidence based healthcare; Medical decision analysis; value of information analysis

Indexed keywords

AGED; ARTICLE; CASE REPORT; COST BENEFIT ANALYSIS; DA; DECISION ANALYSIS; DECISION SUPPORT SYSTEM; DIABETIC FOOT; EA; ENBS; ENTSCHEIDUNGSANALYSE; EVIDENCE BASED MEDICINE; EVIDENCE-BASED HEALTHCARE; EVIDENZ-BASIERTE GESUNDHEITSVERSORGUNG; EVPI; EVPPI; EVSI; EXPECTED NET BENEFIT OF SAMPLING; EXPECTED VALUE OF PARTIAL PERFECT INFORMATION; EXPECTED VALUE OF PERFECT INFORMATION; EXPECTED VALUE OF SAMPLE INFORMATION; FOOT INJURY; GERMANY; HEALTH TECHNOLOGY ASSESSMENT; HTA; HUMAN; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; INCREMENTAL COSTS; INCREMENTAL EFFECTIVENESS; INFORMATION PROCESSING; LE; LIFE EXPECTANCY; LIFE YEARS; LYS; MALE; MEDICAL DECISION ANALYSIS; MEDICAL RESEARCH; MEDIZINISCHE ENTSCHEIDUNGSANALYSE; MORTALITY; NATIONAL HEALTH SYSTEM; NET HEALTH BENEFIT; NET MONETARY BENEFIT; NHB; NHS; NMB; PROBABILISTIC SENSITIVITY ANALYSIS; PSA; QALE; QALYS; QUALITY ADJUSTED LIFE YEAR; QUALITY-ADJUSTED LIFE EXPECTANCY; RANDOMIZED CONTROLLED TRIAL; RCT; RISK ASSESSMENT; STANDARD; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS; SURVIVAL; UNCERTAINTY; VALUE- OF- INFORMATION ANALYSIS; VALUE-OF-INFORMATION; VALUE-OF-INFORMATION ANALYSE; VOI; WILLINGNESS-TO PAY; WILLINGNESS-TO-PAY THRESHOLD; WOUND INFECTION; WTP; ΔC; ΔE; Λ;

DA; DECISION ANALYSIS; EA; ENBS; ENTSCHEIDUNGSANALYSE; EVIDENCE-BASED HEALTHCARE; EVIDENZ-BASIERTE GESUNDHEITSVERSORGUNG; EVPI; EVPPI; EVSI; EXPECTED NET BENEFIT OF SAMPLING; EXPECTED VALUE OF PARTIAL PERFECT INFORMATION; EXPECTED VALUE OF PERFECT INFORMATION; EXPECTED VALUE OF SAMPLE INFORMATION; HEALTH TECHNOLOGY ASSESSMENT; HTA; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; INCREMENTAL COSTS; INCREMENTAL EFFECTIVENESS; LE; LIFE EXPECTANCY; LIFE YEARS; LYS; MEDICAL DECISION ANALYSIS; MEDIZINISCHE ENTSCHEIDUNGSANALYSE; NATIONAL HEALTH SYSTEM; NET HEALTH BENEFIT; NET MONETARY BENEFIT; NHB; NHS; NMB; PROBABILISTIC SENSITIVITY ANALYSIS; PSA; QALE; QALYS; QUALITY-ADJUSTED LIFE EXPECTANCY; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIAL; RCT; VALUE- OF- INFORMATION ANALYSIS; VALUE-OF-INFORMATION; VALUE-OF-INFORMATION ANALYSE; VOI; WILLINGNESS-TO PAY; WILLINGNESS-TO-PAY THRESHOLD; WTP; ΔC; ΔE; Λ;

AGED; BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DECISION SUPPORT TECHNIQUES; DIABETIC FOOT; EVIDENCE-BASED MEDICINE; FOOT INJURIES; GERMANY; HUMANS; LIKELIHOOD FUNCTIONS; MALE; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNCERTAINTY; WOUND INFECTION;

EID: 84890152304     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2013.10.020     Document Type: Article

References (22)

1. U. Siebert When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econom 4 2003 143 150
2. W.F. McGhan, M. Al, J.A. Doshi, I. Kamae, S.E. Marx, and D. Rindress The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report Value Health 12 2009 1086 1099
3. Corro Ramos I, Rutten-van Moelken M, Oppe M,Al M. Prioritizing and designing outcomes research: The role of value of information analysis., 2011, Erasmus University, Institute for Medical Technology Assessment: Rotterdam, the Netherlands. 1-93.
4. M. Sculpher, and K. Claxton Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence? Value Health 8 2005 433 446
5. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, et al. Uncertainty, Evidence and Irrecoverable Costs: Informing Approval, Pricing and Research Decisions for Health Technologies, 2011, Centre for Health Economics, University of York: York, United Kingdom. 1-81.
6. A.E. Ades, G. Lu, and K. Claxton Expected value of sample information calculations in medical decision modeling Med Decis Making 24 2004 207 227
7. B. Groot Koerkamp, M.C. Weinstein, T. Stijnen, M.H. Heijenbrok-Kal, and M.G. Hunink Uncertainty and patient heterogeneity in medical decision models Med Decis Making 30 2010 194 205
8. M.C. Weinstein, H.V. Fineberg, A.S. Elstein, H.S. Frazier, D. Neuhauser, and R.R. Neutra Clinical decision analysisPhiladelphia 1980 Saunders United States 187ff
9. H.J. Trampisch, and J. Windeler Medizinische Statistik 1997 Springer Verlag Berlin Heidelberg New York 147-49
10. M. Drummond, B. O'Brien, G.L. Stoddart, and G.W. Torrance Methods for the economic evaluation of health care programmes 2nd ed. 1997 Oxford University Press New York, United States
11. M. Drummond, and A. McGuire Economic Evaluation in Health Care. Merging Theory with PracticeOxford 2001 Oxford University Press United Kingdom
12. R. Schwarzer, U. Rochau, K. Saverno, B. Jahn, B. Bornschein, and M. Lackner Do existing cost-effectiveness thresholds adequately support decision making for PCM? A review of international practice Med Decis Making 33 2013 E200 E201
13. E.J. MacKenzie, A.S. Jones, M.J. Bosse, R.C. Castillo, A.N. Pollak, and L.X. Webb Health-care costs associated with amputation or reconstruction of a limb-threatening injury J Bone Joint Surg Am 89 2007 1685 1692
14. A.H. Briggs, M.C. Weinstein, E.A. Fenwick, J. Karnon, M.J. Sculpher, and A.D. Paltiel Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6 Med Decis Making 32 2012 722 732
15. M.G.M. Hunink, P.P. Glasziou, J.E. Siegel, J.C. Weeks, J.S. Pliskin, and A.S. Elstein Decision making in health and medicine: integrating evidence and values 2001 Cambridge University Press Cambridge, United Kingdom
16. A.H. Briggs Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 2000 479 500
17. P. Doubilet, C.B. Begg, M.C. Weinstein, P. Braun, and B.J. McNeil Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach Med Decis Making 5 1985 157 177
18. Briggs AH, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation, ed. A. Gray and A.H. Briggs Oxford, New York: Oxford University Press; 2006.
19. A.A. Stinnett, and J. Mullahy Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis Med Decis Making 18 1998 S68 S80
20. K. Claxton, P.J. Neumann, S. Araki, and M.C. Weinstein Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease Int J Technol Assess Health Care 17 2001 38 55
21. K. Claxton, L. Ginnelly, M. Sculpher, Z. Philips, and S. Palmer A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme Health Technol Assess 8 2004 1 103 iii
22. J.J. Carlson, R. Thariani, J. Roth, J. Gralow, N.L. Henry, and L. Esmail Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics Med Decis Making 33 2013 463 471